PL1995242T3 - Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy - Google Patents

Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy

Info

Publication number
PL1995242T3
PL1995242T3 PL07738592T PL07738592T PL1995242T3 PL 1995242 T3 PL1995242 T3 PL 1995242T3 PL 07738592 T PL07738592 T PL 07738592T PL 07738592 T PL07738592 T PL 07738592T PL 1995242 T3 PL1995242 T3 PL 1995242T3
Authority
PL
Poland
Prior art keywords
novel
binding activity
receptor binding
glucocorticoid receptor
tetrahydroquinoxaline derivative
Prior art date
Application number
PL07738592T
Other languages
English (en)
Polish (pl)
Inventor
Mamoru Matsuda
Toshiyuki Mori
Kenji Kawashima
Minoru Yamamoto
Masatomo Kato
Miwa Takai
Masato Nagatsuka
Sachiko Kobayashi
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PL1995242T3 publication Critical patent/PL1995242T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07738592T 2006-03-14 2007-03-14 Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy PL1995242T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006069739 2006-03-14
JP2006255039 2006-08-22
EP07738592A EP1995242B1 (de) 2006-03-14 2007-03-14 Neuartiges 1,2,3,4-tetrahydrochinoxalin-derivat mit glukokortikoidrezeptor-bindeaktivität
PCT/JP2007/055122 WO2007105766A1 (ja) 2006-03-14 2007-03-14 グルココルチコイド受容体結合活性を有する新規１，２，３，４－テトラヒドロキノキサリン誘導体

Publications (1)

Publication Number Publication Date
PL1995242T3 true PL1995242T3 (pl) 2013-03-29

Family

ID=38509582

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07738592T PL1995242T3 (pl) 2006-03-14 2007-03-14 Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy

Country Status (16)

Country Link
US (2) US8551991B2 (de)
EP (1) EP1995242B1 (de)
KR (2) KR20140063907A (de)
CN (1) CN101400659B (de)
AU (1) AU2007225693A1 (de)
BR (1) BRPI0708767A2 (de)
CA (1) CA2643070C (de)
DK (1) DK1995242T3 (de)
ES (1) ES2396711T3 (de)
MX (1) MX2008011779A (de)
NO (1) NO20084262L (de)
PL (1) PL1995242T3 (de)
PT (1) PT1995242E (de)
RU (1) RU2008140525A (de)
SI (1) SI1995242T1 (de)
WO (1) WO2007105766A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2643070C (en) 2006-03-14 2016-01-26 Santen Pharmaceutical Co., Ltd. Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity
PL2151436T3 (pl) * 2007-05-29 2013-09-30 Santen Pharmaceutical Co Ltd Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego
JP2009084273A (ja) * 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd １，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト
WO2009035068A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体
EA018420B1 (ru) * 2008-09-12 2013-07-30 Сантен Фармасьютикал Ко., Лтд. Агонист глюкокортикоидного рецептора, содержащий новые производные 1,2,3,4-тетрагидрохиноксалина с фенильной группой, имеющей структуру эфира сульфоновой кислоты, введенной в нее в качестве заместителя
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
JP2015057381A (ja) * 2013-08-09 2015-03-26 参天製薬株式会社 ３，３−ジメチル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体の製造方法およびその製造方法の中間体
CN106061944A (zh) * 2014-01-24 2016-10-26 普渡制药公司 吡啶类和嘧啶类物质及其用途
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
CN105037425B (zh) * 2015-07-28 2017-06-20 华侨大学 一种喹喔啉‑2(1h)‑酮c‑3位膦酸化合物的合成方法
KR20180043329A (ko) 2015-08-25 2018-04-27 산텐 세이야꾸 가부시키가이샤 [4-(1,3,3-트리메틸-2-옥소-3,4-디히드로-1h-퀴녹살린-7-일)페녹시]에틸옥시 화합물 또는 그의 염
AU2018283250B2 (en) 2017-06-16 2022-09-01 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
US11093563B2 (en) * 2018-02-05 2021-08-17 Microsoft Technology Licensing, Llc Sharing measured values of physical space parameters
TWI811400B (zh) * 2018-07-20 2023-08-11 德商歌林達有限公司 經進一步取代之三唑并喹噁啉衍生物
CN109574811B (zh) * 2018-11-22 2021-12-24 中山大学 一种阿尼芬净侧链中间体对戊氧基三联苯甲酸的制备方法
CN111138398A (zh) * 2019-12-31 2020-05-12 陕西国际商贸学院 一种2-(2-氨基-3-甲氧苯基)色酮的合成工艺
EP4090660B1 (de) * 2020-01-17 2024-01-31 Grünenthal GmbH Chinoxalinderivate
WO2021144440A1 (en) * 2020-01-17 2021-07-22 Grünenthal GmbH Quinoxaline derivatives as modulators of the glucocorticoid receptor
CN115160348A (zh) * 2022-07-06 2022-10-11 中山大学 一种光照下无金属催化的芳香c-h键直接硼化反应的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369057B1 (en) 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
DE59209965D1 (de) 1991-04-15 2002-10-17 Aventis Pharma Gmbh Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
EP1201660B1 (de) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid Rezeptor Modulatoren
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US7235662B2 (en) 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
CN101365696A (zh) * 2004-07-28 2009-02-11 Irm责任有限公司 作为类固醇激素核受体调节剂的化合物和组合物
CA2621292C (en) 2005-09-14 2014-05-27 Santen Pharmaceutical Co., Ltd. 1-2-dihydroquinoline derivative having glucocorticoid receptor binding actvity
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
CA2643070C (en) * 2006-03-14 2016-01-26 Santen Pharmaceutical Co., Ltd. Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PL2085387T3 (pl) 2006-11-14 2013-09-30 Ayumi Pharmaceutical Corp Nowe pochodne 1,2-dihydrochinoliny zawierające jako podstawniki fenylochalkogeno-podstawioną niższą grupę alkilową oraz wprowadzoną przez ester grupę fenylową
JP2008255112A (ja) 2007-03-13 2008-10-23 Santen Pharmaceut Co Ltd ２，２，４−トリメチル−６−フェニル−１，２−ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
PL2151436T3 (pl) 2007-05-29 2013-09-30 Santen Pharmaceutical Co Ltd Nowe pochodne 1,2,3,4-tetrahydrochinoksaliny, które jako podstawnik zawierają grupę fenylową z wprowadzoną strukturą estru kwasu sulfonowego lub amidu kwasu sulfonowego i które mają aktywność wiążącą wobec receptora glukokortykoidowego
WO2009035068A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体
JP2009084273A (ja) 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd １，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト

Also Published As

Publication number Publication date
ES2396711T3 (es) 2013-02-25
AU2007225693A1 (en) 2007-09-20
RU2008140525A (ru) 2010-04-27
CA2643070A1 (en) 2007-09-20
CN101400659B (zh) 2012-02-29
BRPI0708767A2 (pt) 2011-06-14
KR101426966B1 (ko) 2014-08-06
DK1995242T3 (da) 2012-12-17
EP1995242A1 (de) 2008-11-26
WO2007105766A1 (ja) 2007-09-20
EP1995242B1 (de) 2012-11-07
CA2643070C (en) 2016-01-26
KR20140063907A (ko) 2014-05-27
US8975256B2 (en) 2015-03-10
CN101400659A (zh) 2009-04-01
PT1995242E (pt) 2012-11-22
EP1995242A4 (de) 2010-08-04
MX2008011779A (es) 2008-09-25
US20090111807A1 (en) 2009-04-30
KR20080100281A (ko) 2008-11-14
US8551991B2 (en) 2013-10-08
SI1995242T1 (sl) 2013-01-31
US20130303537A1 (en) 2013-11-14
NO20084262L (no) 2008-10-10

Similar Documents

Publication Publication Date Title
PL1995242T3 (pl) Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy
EP1944290A4 (de) Neues 1,2-dihydrochinolinderivat mit glucocorticoidrezeptorbindender aktivität
HUS1900034I1 (hu) 6,7-telítetlen-7-karbamoil-szubsztituált morfinán-származékok
IL189519A0 (en) Chemokine receptor binding compounds
EP1932839A4 (de) Indolcarbonsäurederivat mit antagonistischer wirkung am pgd2-rezeptor
EP1942105A4 (de) Aminodihydrothiazin-derivat
EP2103613A4 (de) Chinoxalinderivat
GB0509275D0 (en) Synthetic receptor
ZA200804534B (en) Formaldehyde-free binder
IL197714A0 (en) 2-pyridinecarboxamide derivative having gk-activating activity
EP1944301A4 (de) Neue benzoxathiinderivate
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
EP1896023A4 (de) Chemokin-rezeptor-bindende verbindungen
EP1893060A4 (de) Bauverbindungselemente
EP1908601A4 (de) Bindevorrichtung
EP1908602A4 (de) Bindevorrichtung
EP1935883A4 (de) Oxindolderivate als mittel zur steuerung der nahrungsaufnahme
ZA200809659B (en) 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
EP1942890A4 (de) Chemokin-rezeptor-bindende verbindungen
GB0509276D0 (en) Synthetic receptor
HK1115123A1 (en) Pyridylmethylsulfone derivative
EP2202231A4 (de) 2,3-dihydroiminoisoindolderivate
EP1914232A4 (de) N-dihydroxyalkyl-substitutierte 2-oxoimidazolderivate
IL190119A0 (en) Amino-alkyl-amide derivatives as ccr3 receptor ligands
IL190093A0 (en) Amino-alkyl-amide derivatives as ccr3 receptor ligands